INNOSPEC INC. (IOSP): what the price assumes

Generated: 2026-07-29 · Exported: 2026-08-01 · Source: https://boothcheck.com/report/IOSP

Headline

Field	Value
Ticker	IOSP
Company	INNOSPEC INC.
Current price	$85.40/sh
Composition	Personal Care (Performance Chemicals) 23% / Home Care (Performance Chemicals) 6% / Other (Performance Chemicals) 9% / Refinery and Performance (Fuel Specialties) 29% / Other (Fuel Specialties) 11% / Oilfield Services 22%

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

Field	Value
Inversion basis	whole-company
Operating margin (value-band context)	2.9%
Operating margin today	6.9%
Margin compression (value-band)	-4.0pp
Implied growth	9.2%
Multiple paid	15x operating income

The operating-margin figure is value-band context at year 12: derived from the framework's value band, a separate calculation — not part of the priced-in solve.

Solve inputs: computed at a 9.5% cost of capital with 4% terminal growth over a 5-year stage; each 1pp of cost of capital moves the implied operating-profit growth ~6.1pp.

How unusual the bet is: within-range

Reference	Value
vs own history	-0.30σ
cohort percentile (of 80 peers)	35
implied end-window share	0%

Valuation X-Ray

The price is justified by relative-multiple; asset-based land below the price.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

Family	Median price/FV	Models	Reads
Asset	1.79x	5	expensive
Earnings	1.43x	5	expensive
Relative	0.98x	5	justifies
Growth	1.30x	3	expensive

Families that justify the price: Relative Families that call it expensive: Asset

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 8.8%); the inversion above states its own rate.

Per-Model Detail (n=18)

Model	Family	FV	Price/FV	Applicable	Methodology
DCF Perpetual Growth	Growth	$65.55	1.30x	yes	FCF base $0.1B, growth 0% (input: historical growth), terminal g 0.5%, WACC 8.8%, 5yr projection
DCF Exit Multiple	Growth	$82.45	1.04x	yes	Exit EV/EBITDA: 13.1x / 15.1x / 17.1x (bear / base = today's held flat / bull), 5yr
Relative Valuation	Relative	$61.60	1.39x	yes	P/E 14x (static sector reference · 2026-04), scenarios: 11.8x / 14.0x / 16.2x (bear / base = reference held flat / bull), EV/EBITDA 10.13x
Simple DDM	Growth	—	—	no	—
Two-Stage DDM	Growth	—	—	no	—
Simple Excess Return	Asset	$49.69	1.72x	yes	BV/sh $54.14, ROE (TTM) 8.5%, ke 9.3%
Two-Stage Excess Return	Asset	$47.60	1.79x	yes	5yr excess ROE then converge to ke=9.3%
Discounted Future Market Cap	Growth	$55.47	1.54x	yes	Rev $1.8B, growth 0% (input: historical growth; tapered), Terminal P/S: 1.0x / 1.2x / 1.4x (bear / base = today's held flat / bull, cap 8x)
Peter Lynch Fair Value	Relative	$86.90	0.98x	yes	EPS $4.58, growth 19% (input: historical EPS growth), PEG=0.98 (Undervalued)
Margin Trajectory	Growth	—	—	no	—
Earnings Power Value	Earnings	$62.17	1.37x	yes	Normalized EBIT (5y avg op income, one-time charges added back) $0.16B × (1−23%) / WACC 8.8% → EPV (no growth)
Residual Income	Asset	$47.26	1.81x	yes	BV $54.14 + 5yr PV of (ROE (TTM) 8.5% − Kₑ 9.3%) × BV; BV grows 5.5%/yr
Graham Number	Asset	$74.69	1.14x	yes	√(22.5 × EPS $4.58 × BVPS $54.14) — Graham's conservative floor
EV/EBITDA Relative	Relative	$47.21	1.81x	yes	EBITDA $0.13B × sector EV/EBITDA 8.0x
FCF Yield	Earnings	$59.78	1.43x	yes	FCF $127.6M / Kₑ 9.3% — zero-growth perpetuity
SBC-Adj FCF Yield	Earnings	$56.34	1.52x	yes	SBC-adj FCF $0.12B (FCF $0.13B − SBC $0.01B) capitalized at Kₑ
Ben Graham Formula	Earnings	$147.78	0.58x	yes	EPS $4.58 × (8.5 + 2×15.0%) × (4.4 / 5.3%)
ROIC-Justified P/B	Asset	$13.95	6.12x	yes	BV $54.14 × (ROIC 2.3% / WACC 8.8%)
P/Sales Sector	Relative	$108.10	0.79x	yes	Revenue $1.79B × sector P/S 1.5x
PEG Fair Value	Relative	$130.34	0.66x	yes	EPS $4.58 × (PEG 1.5 × growth 19.0% (input: historical EPS growth)) → PE 28.5x
Earnings Yield	Earnings	$49.51	1.72x	yes	EPS $4.58 / required return 9.3% (Rf 4.3% + ERP 5.0%)
Funds From Operations Multiple	Relative	—	—	no	—
Clinical Phase NPV	Growth	—	—	no	—
Merton	Asset	—	—	no	—
V5 Mechanical	—	—	—	no	—

Solvency

Field	Value
Net cash	$289.1m
Net debt / NOPAT (after-tax)	-3.03x (net cash)
Net debt / operating income (pre-tax)	-2.34x (net cash)
Share count CAGR (buyback)	-0.1%
Burning cash	no

Interest expense is not separately reported in the latest filings, so interest coverage cannot be computed.

Bullet Takeaways

• Innospec is a specialty-chemicals company split across three segments, fuel additives, performance chemicals for personal care and home care, and oilfield services, each holding niche, defensible positions rather than competing on scale.
• The near-term risk is margin: first-quarter 2026 gross margin slipped to 27.3% as a U.S. winter storm cut Performance Chemicals operating income 46%, and management flagged Middle East-related pressure on raw materials.
• The balance sheet is the standout strength: $289 million of net cash, no debt, a 10% dividend increase, and a new $75 million buyback.

Bull Case

Innospec is best understood as a mature, cash-generative specialty-chemicals operator rather than a growth story, and reading it through that stage is what makes the bull case coherent. A specialty-chemicals company does not win by being the biggest; it wins by occupying narrow product niches where it has technical leadership and few competitors. Innospec describes its Fuel Specialties segment as "generally characterized by a small number of competitors, none of which hold a dominant position", with its edge in proven technical capability. That is the whole model: pick markets too small or too specialized for the chemical majors to bother with, and own them.

The portfolio spreads that approach across three end markets that do not move together. Fuel additives improve engine performance and reduce emissions; performance chemicals serve personal and home care; and oilfield services supplies drilling and production chemicals including drag-reducing agents. When one segment hits a rough patch, the others can offset it, which is exactly what happened in the most recent quarter when Fuel Specialties and Oilfield Services posted higher operating income while Performance Chemicals absorbed a storm-related hit. Diversification across uncorrelated chemistries is a quieter moat than a single dominant product, but it is a real one.

The capital position is what a mature compounder should look like. Innospec carries $289 million of net cash and no debt, and in the most recent quarter it raised its semi-annual dividend 10% and authorized a fresh $75 million buyback. A debt-free balance sheet in a cyclical, raw-material-exposed industry is both a shock absorber and an option: it lets the company keep paying shareholders through soft patches and gives it the firepower to acquire bolt-on niche product lines, the way specialty-chemicals companies have always grown. The price reflects this profile, supported by the relative-multiple method as a steady, cash-returning business rather than a high-growth bet.

Bear Case

The variable with the most leverage on Innospec's near-term results is one it cannot control: the cost and availability of raw materials, which sit at the mercy of energy prices and geopolitics. Management explicitly flagged the Middle East conflict as a potential pressure on raw materials, customer activity, and near-term margins. A specialty-chemicals company buys petrochemical feedstocks and sells formulated products; when feedstock costs spike faster than it can reprice, the margin gets squeezed in the middle. The first quarter showed exactly this, with gross margin compressing to 27.3% and Performance Chemicals operating income falling 46% on a combination of a winter storm and cost pressure.

The growth profile is the structural challenge underneath the macro noise. These are mature end markets, fuel additives, established personal-care chemistries, oilfield chemicals, growing roughly with industrial activity rather than secularly. Revenue rose just 3% in the most recent quarter, and adjusted EBITDA actually declined year over year. The price is reached only by the relative-multiple method; the asset-based lens calls it expensive. That tells you the market is paying a peer multiple for a business whose earnings are flat to down, which works as long as the multiple holds but offers little cushion if margins stay pressured and growth stays muted.

The segment concentration cuts both ways. The same diversification that cushions one bad segment also means no single engine is large or fast enough to carry the company to a higher growth rate. Performance Chemicals, the consumer-facing segment, is the one most exposed to discretionary demand and the one that just took the biggest hit. The balance sheet removes any solvency worry, net cash and no debt, so this is not a distress bear. It is a margins-and-growth bear: a well-capitalized, well-run company in mature markets, where the earnings power is being pressured by costs it does not set and the multiple has limited room to expand.

Valuation

The right way to value Innospec is as a steady cash compounder, not a growth name, and the price reflects that. The relative-multiple method supports the current price, valuing the company in line with its specialty-chemicals peers, while the asset-based lens calls it expensive against book value. The implied forward profile is modest growth in the low double digits at most, which matches a business whose revenue grew 3% in the most recent quarter. There is no aggressive assumption embedded here; the price is paying for continuity, not acceleration.

The live debate is margin durability rather than growth. The first quarter saw gross margin compress to 27.3% and Performance Chemicals operating income fall sharply on a storm and cost pressure, while Fuel Specialties and Oilfield Services held up better. The price assumes these pressures are transient, management is cautiously optimistic about sequential improvement in the second quarter, rather than the start of a structural margin reset driven by raw-material costs. That is the assumption a buyer underwrites: that the diversified portfolio reverts toward its normal margin once the one-time items roll off. Among chemicals peers, this is a name priced on demonstrated, mid-cycle earnings rather than on a re-rating thesis.

Solvency is not a question at all, and that is the anchor under the downside. Innospec holds $289 million of net cash with no debt, which is why it can raise the dividend 10% and launch a $75 million buyback even in a soft quarter. A debt-free specialty-chemicals company can fund shareholder returns and opportunistic acquisitions through a downturn without strain. The decisive variable is the margin trajectory, not the balance sheet: the price is fair for a steady cash generator, and it stays fair as long as the margin pressure proves cyclical rather than permanent.

Catalysts

The most recent quarter, the first of 2026, was a revenue beat shadowed by margin pressure. Revenue rose 3% year over year to $453.2 million, ahead of forecasts, with GAAP diluted EPS of $1.22, but adjusted EBITDA of $43.7 million declined from the prior year and gross margin slipped 1.1 points to 27.3%. The segment split told the story: Fuel Specialties and Oilfield Services posted higher operating income, while Performance Chemicals operating income fell 46% to $10.7 million, hit by a January 2026 U.S. winter storm and a plant shutdown.

Management paired the soft quarter with stronger capital returns. The board raised the semi-annual dividend 10% to $0.92 and approved a new $75 million buyback, of which $6.2 million was repurchased in the quarter. With $289.1 million of net cash and no debt, the company has the balance sheet to keep returning capital through a soft patch.

The forward watch items are margins and macro. Management was cautiously optimistic about sequential operating improvement in the second quarter as the storm effects roll off, but it also flagged the Middle East conflict as a potential pressure on raw-material costs, customer activity, and near-term margins. The second-quarter print is the test of whether the first-quarter weakness was a one-off or the start of a margin reset.

Peer Cohorts (Per Segment, With Filing Citations)

Performance Chemicals (reported)

• SXT (Sensient Technologies Corp)
• FY2025 10-K: …positions as of December 31, 2025. As part of its commitment to quality as a competitive advantage, the Company's production facilities hold various certifications, such as those under the International Organization for Standardization (ISO) and those recognized by the Global Food Safety Initiative (GFSI), including…
• FY2025 10-K: …exceptions, the Company is no longer subject to federal, state, and local, or non-U.S. income tax examinations by tax authorities for years before 2021. 12. Segment and Geographic Information The accounting policies of the segments are the same as those described in the summary of significant accounting policies. The…
• AVNT (AVIENT CORPORATION)
• FY2025 10-K: …No customer accounted for more than 3% of our consolidated revenues in 2025. Research and Development One of our strategic drivers is to "Amplify Innovation," and we have substantial technology and development capabilities, powered by approximately 1,100 employees serving in technical capacities, approximately 120 of…
• FY2025 10-K: …cooling, anti-static, electrostatic discharge, and electromagnetic shielding performance for critical applications including integrated circuit chip packaging. Various additives can also be formulated with a base resin and further engineered into a composite to provide them with greater versatility and performance.…
• IFF (INTERNATIONAL FLAVORS & FRAGRANCES INC)
• FY2025 10-K: …for fresh dairy, cheese, bakery and brewing products. Such products contribute to extended shelf life, stability, taste, and texture, helping IFF's customers to improve their product offerings. The business's enzyme solutions also allow IFF's customers to provide low sugar, high fiber and lactose-free dairy products.…
• FY2025 10-K: …regulations, and although the impact of future changes cannot be predicted with certainty, compliance has not had, and is not expected to have, a material adverse effect on our capital expenditures, earnings, or competitive position. Our products and operations are regulated by governmental agencies in the local…
• CBT (Cabot Corporation)
• FY2025 10-K: …that demand; ii) changes in raw material costs and our ability to adjust the sales price for our products commensurate with changes in raw material costs; iii) changes in pricing and product mix, which includes customer pricing as well as the mix of products sold or the region in which they are sold; iv) global and…
• FY2025 10-K: In fiscal 2025, sales in Reinforcement Materials decreased by $269 million compared to fiscal 2024. The decrease was primarily due to lower volumes ($125 million) and less favorable pricing and product mix ($127 million). The lower volumes were primarily due to lower customer demand driven by uncertainty from tariffs…
• NGVT (INGEVITY CORPORATION)
• FY2025 10-K: …application. Additionally, we are well-positioned to meet increasingly stringent emissions standards worldwide. 10 Performance Chemicals Our Performance Chemicals segment is comprised of two product lines: pavement technologies and road markings. Our Performance Chemicals products are utilized in asphalt pavement…
• FY2025 10-K: …production for ICE powertrains compared to the prior year. We expect Net sales in our Performance Chemicals reportable segment, inclusive of the road markings product line, to grow mid-single digits through continued adoption of our warm mix asphalt products in our pavement technologies product line. For our Advanced…
• FUL (FULLER H B CO)
• FY2025 10-K: …new high-performance solutions that enable customers to improve their products and processes to better achieve their sustainability programs. Regulatory Compliance The Company is subject to various federal, state, local and foreign laws and regulations relating to environmental protection and workers' safety,…
• FY2025 10-K: Research and Development Our investment in research and development creates new and innovative adhesive technology platforms, enhances product performance, ensures a competitive cost structure and leverages available raw materials. New product development is a key research and development outcome, providing…
• ECVT (Ecovyst Inc.)
• FY2025 10-K: …raw materials include spent sulfuric acid, sulfur, acids, bases (including sodium hydroxide, or "caustic soda") and certain metals. Spent sulfuric acid for our regeneration services product group is supplied by customers as part of their contracts. Most of our contracts feature take-or-pay volume protection and/or…
• FY2025 10-K: …with performance conditions stipulate that the performance vesting condition can be attained for a period of six months following separation from service under certain circumstances, depending on the means of separation from the Company and subject to other factors such as individual separation agreements. The same…
• KWR (QUAKER CHEMICAL CORPORATION)
• FY2025 10-K: …through its own employees and its Fluidcare TM programs, with the balance sold through distributors and agents. The Company's employees typically visit the plants of customers regularly, work on site, and through training and experience, identify production needs which can be resolved or otherwise addressed either by…
• FY2025 10-K: …customer could have a material adverse effect on our business. 7 We may not be able to timely develop, manufacture and gain market acceptance of new and enhanced products required to maintain or expand our business, which could adversely affect our competitive position and our liquidity, financial position and…

Fuel Specialties (reported)

• NEU (NEWMARKET CORPORATION)
• FY2025 10-K: …for heavy machinery. Additionally, as a leading additive supplier to the electric vehicle market, we are investing in and delivering new technologies to enable electric vehicle market growth to help reduce carbon emissions. We anticipated and are responding to the need for future lubricants to consider conductivity,…
• FY2025 10-K: …in quarterly results for the specialty materials segment on an ongoing basis due to the nature of the business, including any impact from shutdowns of the U.S. government. Our business typically generates significant amounts of cash beyond its operational needs. We regularly review our many internal opportunities to…
• WDFC (WD-40 COMPANY)
• FY2025 10-K: …our financial condition and results of operations may be negatively impacted. In addition, a change in the strategies of our existing customers, including shelf simplification, the discontinuation of certain product offerings or the shift in shelf space to competitors' products could reduce our sales and potentially…
• FY2025 10-K: …the Marksman ® Spout to deliver precise application to small mechanisms and assemblies, tool maintenance and threads on screws and bolts. 3-IN-ONE Oil is the market share leader among drip oils in many countries. It also has wide industrial applications in such areas as locksmithing, HVAC, marine, farming and…
• SXT (Sensient Technologies Corp)
• FY2025 10-K: …positions as of December 31, 2025. As part of its commitment to quality as a competitive advantage, the Company's production facilities hold various certifications, such as those under the International Organization for Standardization (ISO) and those recognized by the Global Food Safety Initiative (GFSI), including…
• FY2025 10-K: • Flavors & Extracts. Competition in the flavors, extracts, and flavor ingredients industries continues to have an ever-increasing global nature. Most of the Company's customers do not buy all of their flavor and flavor ingredients products from a single supplier, and the Company does not compete with a single…
• NGVT (INGEVITY CORPORATION)
• FY2025 10-K: …in gasoline vapor emission control systems in internal combustion engines and hybrid electric vehicles including cars, trucks, motorcycles, and boats. We also produce several other activated carbon products for food, water, beverage, and chemical purification applications. Our Performance Chemicals segment products…
• FY2025 10-K: …and consistent profitability: Performance Materials and Pavement Technologies. New Ingevity's businesses will be focused on high-value, mission-critical applications that benefit from durable, long-term demand and will allow Ingevity to retain our global scale, maintain a strong pro forma financial profile, and…

Oilfield Services (reported)

• LYB (LYONDELLBASELL INDUSTRIES N.V.)
• FY2025 10-K: …and Derivatives ("I&D") segment, new octane capacity pressured oxyfuels and related products margins through most of the summer driving season. Our APS segment delivered meaningful gains through margin improvement, portfolio optimization and increased business win rates. In 2025, we agreed to sell certain European…
• FY2025 10-K: …advantaged feedstocks and attractive returns. Building a profitable Circular & Low Carbon Solutions ("CLCS") business -We expect our CLCS business will grow to become a leader in meeting the rapidly growing demand for sustainable solutions at scale. We are building a comprehensive platform for sourcing recycled and…
• DOW (Dow Inc.)
• FY2025 10-K: …UCARSOL ™ Amines and related technology for carbon capture and gas treating, ethanolamines, ethylene oxide ("EO"), ethyleneamines, ELEVATE ™ Additives for enhanced oil recovery, UCON ™ Fluids, DOWANOL ™ Glycol Ethers, DOWTHERM ™ Heat Transfer Fluids, DOWFROST ™ Fluids for data center cooling; higher glycols,…
• FY2025 10-K: …optimize its global asset footprint. Additionally, the Company recognized a $303 million pretax impairment charge related to assets used for chlor-alkali, propylene oxide and brine production in Latin America due to challenging economic conditions in the region. The impairment charge included $71 million related to…
• OLN (Olin Corporation)
• FY2025 10-K: …such as converted epoxy resins and additives, which represented 20% of 2025 sales. The Winchester segment produces and sells sporting ammunition, reloading components, small caliber military ammunition and components, industrial cartridges and clay targets, along with contracted U.S. military project revenue, which…
• FY2025 10-K: …Foreign Jurisdictions that Prevent Inspections 99 Part III 100 Item 10. Directors, Executive Officers and Corporate Governance 100 Item 11. Executive Compensation 100 Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 100 Item 13. Certain Relationships and Related…
• CE (CELANESE CORPORATION)
• FY2025 10-K: …traditional vinyl-based end uses, such as paints and coatings and adhesives, as well as other unique, high-value end uses including flexible packaging, thermal laminations, wire and cable, and compounds. Our acetyl products produce and supply acetic acid, acetic anhydride and acetate esters and VAM. These products…
• FY2025 10-K: …Fragrances Corporation, No. 2:23-cv-1699 (U.S. District Court New Jersey) (the "2023 OCC Lawsuit"). Like the earlier lawsuit, the 2023 OCC Lawsuit concerns the facility Essex County, New Jersey purchased and for which Essex County, New Jersey has agreed to defend and indemnify the Company. This new lawsuit does not…
• EMN (EASTMAN CHEMICAL CO)
• FY2025 10-K: …expenses, other components of post-employment (benefit) cost, net, and other (income) charges, net. (2) Other is not considered an operating segment. Other includes sales and costs from growth initiatives and businesses, R&D costs, pension and other postretirement benefit plans income (expense), net, and other income…
• FY2025 10-K: …an operating segment. Other includes the following which are not allocated to operating segments: 1) sales and costs from growth initiatives and businesses, 2) pension and other postretirement benefit plans income (expense), net, and 3) other income (charges), net. (3) See Note 16, "Asset Impairments, Restructuring,…
• HUN (Huntsman Corporation)
• FY2025 10-K: …the date made. We undertake no obligation to publicly update or revise forward-looking statements whether because of new information, future events or otherwise, except as required by securities and other applicable law. There are a number of risks and uncertainties that could cause our actual results to differ…
• FY2025 10-K: :PensionPlansDefinedBenefitMember 2025-12-31 0001307954 hun:RealEstateAndOtherMember us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2025-12-31 0001307954 us-gaap:DefinedBenefitPlanCashMember country:US us-gaap:PensionPlansDefinedBenefitMember 2025-12-31 0001307954…

Methodology Note

• Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
• Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
• Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
• Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.

Sources

Innospec Q1 2026 earnings call · Innospec Q1 2026 earnings release